The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Management of multidrug-resistant enterococcal infections
Open accessAbstract
Enterococci are organisms with a remarkable ability to adapt to the environment and acquire antibiotic resistance determinants. The evolution of antimicrobial resistance in these organisms poses enormous challenges for clinicians when faced with patients affected with severe infections. The increased prevalence and dissemination of multidrug-resistant Enterococcus faecium worldwide has resulted in a major decrease in therapeutic options because the majority of E. faecium isolates are now resistant to ampicillin and vancomycin, and exhibit high-level resistance to aminoglycosides, which are three of the traditionally most useful anti-enterococcal antibiotics. Newer antibiotics such as linezolid, daptomycin and tigecycline have good in vitro activity against enterococcal isolates, although their clinical use may be limited in certain clinical scenarios as a result of reduced rates of success, possible underdosing for enterococci and low serum levels, respectively, and also by the emergence of resistance. The experimental agent oritavancin may offer some hope for the treatment of vancomycin-resistant enterococci but clinical data are still lacking. Thus, optimal therapies for the treatment of multidrug-resistant enterococcal infections continue to be based on empirical observations and extrapolations from in vitro and animal data. Clinical studies evaluating new strategies, including combination therapies, to treat severe vancomycin-resistant E. faecium infections are urgently needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hidron, A. I., Edwards, J. R., Patel, J., Horan, T. C., Sievert, D. M., Pollock, D. A., Fridkin, S. K., & National Healthcare Safety Network Team and Participating National Healthcare Safety Network Facilities (2008) · Infection Control & Hospital Epidemiology · doi:10.1086/591861 · Cited by 3,724
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Bolger, A. F., Levison, M. E., Ferrieri, P., Gerber, M. A., Tani, L. Y., Gewitz, M. H., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.165564 · Cited by 1,707
Vancomycin-Resistant Enterococcal Infections
Murray, B. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003093421007 · Cited by 890
Self-citationCorrelation of Daptomycin Bactericidal Activity and Membrane Depolarization in Staphylococcus aureus
Silverman, J. A., Perlmutter, N. G., & Shapiro, H. M. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.8.2538-2544.2003 · Cited by 656
Emergence and spread of vancomycin resistance among enterococci in Europe
Werner, G., Coque, T. M., Hammerum, A. M., Hope, R., Hryniewicz, W., Johnson, A., Klare, I., Kristinsson, K. G., Leclercq, R., Lester, C. H., et al. (2008) · Eurosurveillance · doi:10.2807/ese.13.47.19046-en · Cited by 539
Birmingham, M. C., Rayner, C. R., Meagher, A. K., Flavin, S. M., Batts, D. H., & Schentag, J. J. (2003) · Clinical Infectious Diseases · doi:10.1086/345744 · Cited by 428
Higgins, D. L., Chang, R., Debabov, D. V., Leung, J., Wu, T., Krause, K. M., Sandvik, E., Hubbard, J. M., Kaniga, K., Schmidt, D. E., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.3.1127-1134.2005 · Cited by 425
Ellis‐Grosse, E. J., Babinchak, T., Dartois, N., Rose, G., Loh, E., & Groups, T. 3. A. 3. C. S. (2005) · Clinical Infectious Diseases · doi:10.1086/431675 · Cited by 414
Babinchak, T., Ellis‐Grosse, E., Dartois, N., Rose, G. M., Loh, E., & Groups, T. 3. A. 3. S. (2005) · Clinical Infectious Diseases · doi:10.1086/431676 · Cited by 381
Toh, S., Xiong, L., Arias, C. A., Villegas, M. V., Lolans, K., Quinn, J., & Mankin, A. S. (2007) · Molecular Microbiology · doi:10.1111/j.1365-2958.2007.05744.x · Cited by 338 · cited 1×
“Linezolid is an oxazolidinone antibiotic that inhibits bacterial ribosomal protein synthesis [44].”
BackgroundSelf-citationAminoglycoside Resistance in Enterococci
Chow, J. W. (2000) · Clinical Infectious Diseases · doi:10.1086/313949 · Cited by 332
Studies on antibiotic synergism against enterococci
Moellering, R. C., & Weinberg, A. N. (1971) · Journal of Clinical Investigation · doi:10.1172/jci106758 · Cited by 302
Emergence and management of drug-resistant enterococcal infections
Arias, C. A., & Murray, B. E. (2008) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.6.5.637 · Cited by 294
Self-citationSingh, K. V., Weinstock, G. M., & Murray, B. E. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.6.1845-1850.2002 · Cited by 263 · cited 1×
“Q/D inhibits protein synthesis by interacting with the 50S ribosomal subunit [56,57] and several mechanisms of resistance have been documented in enterococci [58,59].”
BackgroundSelf-citationMurray, B. E., & Mederski-Samaroj, B. (1983) · Journal of Clinical Investigation · doi:10.1172/jci111042 · Cited by 253
Self-citationInterscience Conference on Antimicrobial Agents and Chemotherapy
(1961) · Folia Microbiologica · doi:10.1007/bf02864650 · Cited by 252
Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report
Peleg, A. Y., Potoski, B. A., Rea, R., Adams, J., Sethi, J., Capitano, B., Husain, S., Kwak, E. J., Bhat, S. V., & Paterson, D. L. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl441 · Cited by 248
Tigecycline: A New Glycylcycline for Treatment of Serious Infections
Noskin, G. A. (2005) · Clinical Infectious Diseases · doi:10.1086/431672 · Cited by 226
High-Level Resistance to Gentamicin in Clinical Isolates of Enterococci
Mederski-Samoraj, B. D., & Murray, B. E. (1983) · Journal of Infectious Diseases · doi:10.1093/infdis/147.4.751 · Cited by 213
Self-citationGavaldà, J., Len, O., Miró, J. M., Muñoz, P., Montejo, M., Alarcón, A., de la Torre-Cisneros, J., Peña, C., Martínez-Lacasa, X., Sarria, C., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-8-200704170-00008 · Cited by 202
Beta-lactamase-producing enterococci
Murray, B. E. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.11.2355 · Cited by 182
Self-citationReductive Alkylation of Glycopeptide Antibiotics: Synthesis and Antibacterial Activity.
COOPER, R. D. G., SNYDER, N. J., ZWEIFEL, M. J., STASZAK, M. A., WILKIE, S. C., NICAS, T. I., MULLEN, D. L., BUTLER, T. F., RODRIGUEZ, M. J., HUFF, B. E., et al. (1996) · The Journal of Antibiotics · doi:10.7164/antibiotics.49.575 · Cited by 181
Akins, R. L., & Rybak, M. J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.2.454-459.2001 · Cited by 179
Oritavancin Kills Stationary-Phase and Biofilm Staphylococcus aureus Cells In Vitro
Belley, A., Neesham-Grenon, E., McKay, G., Arhin, F. F., Harris, R., Beveridge, T., Parr, T. R., & Moeck, G. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00766-08 · Cited by 178
Inhibition of protein synthesis by streptogramins and related antibiotics
Cocito, C., Di Giambattista, M., Nyssen, E., & Vannuffel, P. (1997) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/39.suppl_1.7 · Cited by 176
Falagas, M. E. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl219 · Cited by 167 · cited 1×
“apy in this study [48].”
Synergistic effect of amoxicillin and cefotaxime against Enterococcus faecalis
Mainardi, J. L., Gutmann, L., Acar, J. F., & Goldstein, F. W. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.9.1984 · Cited by 164
Reid, K. C., Cockerill, F. R., & Patel, R. (2001) · Clinical Infectious Diseases · doi:10.1086/320542 · Cited by 156
Arias, C. A., Vallejo, M., Reyes, J., Panesso, D., Moreno, J., Castañeda, E., Villegas, M. V., Murray, B. E., & Quinn, J. P. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.01886-07 · Cited by 135
Self-citationNew antimicrobial agents for the treatment of Gram-positive bacterial infections
Aksoy, D. Y., & Ünal, S. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2007.01933.x · Cited by 124
Entenza, J. M., & Moreillon, P. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2008.11.006 · Cited by 120
Enterococcal Endocarditis: A Comparison of Prosthetic and Native Valve Disease
Rice, L. B., Calderwood, S. B., Eliopoulos, G. M., Farber, B. F., & Karchmer, A. W. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/13.1.1 · Cited by 116
Mechanism of Resistance to Antibiotic Synergism in Enterococci
Zimmermann, R. A., Moellering, R. C., & Weinberg, A. N. (1971) · Journal of Bacteriology · doi:10.1128/jb.105.3.873-879.1971 · Cited by 112
Mechanisms of Resistance to Imipenem and Ampicillin in Enterococcus faecalis
Ono, S., Muratani, T., & Matsumoto, T. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.7.2954-2958.2005 · Cited by 111
Infections Due to Beta-Lactamase-producing, High-Level Gentamicin-resistant Enterococcus faecalis
Wells, V. D., Wong, E. S., Murray, B. E., Coudron, P. E., Williams, D. S., & Markowitz, S. M. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-116-4-285 · Cited by 105
Self-citationLautenbach, E., Schuster, M. G., Bilker, W. B., & Brennan, P. J. (1998) · Clinical Infectious Diseases · doi:10.1086/515002 · Cited by 100
Treatment of Vancomycin‐ResistantEnterococcus faeciumInfections with Quinupristin/Dalfopristin
Linden, P. K., Moellering, R. C., Wood, C. A., Rehm, S. J., Flaherty, J. P., Bompart, F., Talbot, G. H., & Synercid Emergency‐Use Study Group (2001) · Clinical Infectious Diseases · doi:10.1086/323899 · Cited by 95
Vancomycin and Oritavancin Have Different Modes of Action in Enterococcus faecium
Patti, G. J., Kim, S. J., Yu, T., Dietrich, E., Tanaka, K. S. E., Parr, T. R., Far, A. R., & Schaefer, J. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.06.064 · Cited by 87
Enoch, D., Bygott, J. M., Daly, M., & Karas, J. A. (2007) · Journal of Infection · doi:10.1016/j.jinf.2007.05.180 · Cited by 85
Arias, C. A., Torres, H. A., Singh, K. V., Panesso, D., Moore, J. E., Wanger, A. R., & Murray, B. E. (2007) · Clinical Infectious Diseases · doi:10.1086/522656 · Cited by 84
Self-citationWerner, G., Gfrörer, S., Fleige, C., Witte, W., & Klare, I. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn065 · Cited by 84
Endocarditis Due to Vancomycin-Resistant Enterococci: Case Report and Review of the Literature
Stevens, M., & Edmond, M. B. (2005) · Clinical Infectious Diseases · doi:10.1086/444459 · Cited by 82
Pankey, G. A., Ashcraft, D. S., & Patel, N. B. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.12.5166-5168.2005 · Cited by 82
MULTIDRUG-RESISTANT ENTEROCOCCUS FAECIUM MENINGITIS IN A TODDLER
Jaspan, H. B., Brothers, A. W., Campbell, A. J. P., McGuire, J. K., Browd, S. R., Manley, T. J., Pak, D., & Weissman, S. J. (2010) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3181c806d8 · Cited by 79
Critchley, I. A., Blosser-Middleton, R. S., Jones, M. E., Thornsberry, C., Sahm, D. F., & Karlowsky, J. A. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.5.1689-1693.2003 · Cited by 75
Matsumura, S., & Simor, A. E. (1998) · Clinical Infectious Diseases · doi:10.1086/517755 · Cited by 73
Tigecycline: A Novel Broad-Spectrum Antimicrobial
Slover, C. M., Rodvold, K. A., & Danziger, L. H. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1h543 · Cited by 72
Brown, D. F., Hope, R., Livermore, D. M., Brick, G., Broughton, K., George, R. C., Reynolds, R., & Surveillance, O. B. O. T. B. W. P. O. R. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn354 · Cited by 69
Brandt, C. M., Rouse, M. S., Laue, N. W., Stratton, C. W., Wilson, W. R., & Steckelberg, J. M. (1996) · Journal of Infectious Diseases · doi:10.1093/infdis/173.4.909 · Cited by 64
Jenkins, I. (2007) · Journal of Hospital Medicine · doi:10.1002/jhm.236 · Cited by 61
Schutt, A. C., & Bohm, N. M. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1m324 · Cited by 57 · cited 1×
“More recently, two case reports have documented the successful combination of high-dose daptomycin with tigecycline in the treatment of endocarditis [41,42].”
BackgroundArias, C. A., Singh, K. V., Panesso, D., & Murray, B. E. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00131-07 · Cited by 55
Self-citationSnydman, D. R., McDermott, L. A., & Jacobus, N. V. (2005) · Journal of Chemotherapy · doi:10.1179/joc.2005.17.6.614 · Cited by 49
Evaluation of ceftobiprole medocaril against Enterococcus faecalis in a mouse peritonitis model
Arias, C. A., Singh, K. V., Panesso, D., & Murray, B. E. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm237 · Cited by 49
Self-citationTsigrelis, C., Singh, K. V., Coutinho, T. D., Murray, B. E., & Baddour, L. M. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.02188-06 · Cited by 48 · cited 1×
“1) [49–51].”
Self-citationQuinupristin/Dalfopristin (RP 59500): A New Streptogramin Antibiotic
Chant, C. A., & Rybak, M. J. (1995) · Annals of Pharmacotherapy · doi:10.1177/106002809502901013 · Cited by 47
Singh, K. V., & Murray, B. E. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.1.32-39.2005 · Cited by 47
Self-citationLeonard, S. N., & Rybak, M. J. (2008) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.28.4.458 · Cited by 46
FURTHER OBSERVATIONS ON THE ZONE PHENOMENON IN THE BACTERICIDAL ACTION OF PENICILLIN
Eagle, H. (1951) · Journal of Bacteriology · doi:10.1128/jb.62.5.663-668.1951 · Cited by 41
Failure of Linezolid Treatment for Enterococcal Endocarditis
Zimmer, S. M., Caliendo, A., Thigpen, M. C., & Somani, J. (2003) · Clinical Infectious Diseases · doi:10.1086/375877 · Cited by 38
Jacqueline, C., Caillon, J., Mabecque, V. L., Miegeville, A.-F., Ge, Y., Biek, D. P., Batard, É., & Potel, G. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00984-09 · Cited by 37
Rice, L. B., Eliopoulos, G. M., & Moellering, R. C. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.4.470 · Cited by 36
Antony, S. J., Ladner, J. M., Stratton, C. W., Raudales, F., & Dummer, S. J. (1997) · Scandinavian Journal of Infectious Diseases · doi:10.3109/00365549709035908 · Cited by 21
Landman, D., Quale, J. M., Mobarakai, N. K., & Zaman, M. M. (1995) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/36.1.253 · Cited by 20
Short-term success, but long-term treatment failure with linezolid for enterococcal endocarditis
Berdal, J., & Eskesen, A. N. (2008) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540802087209 · Cited by 15
Vancomycin-resistant Enterococcus faecium Meningitis Successfully Treated with Linezolid
Mizell, K. N., & Carter, J. E. (2008) · Southern Medical Journal · doi:10.1097/smj.0b013e31816c01ef · Cited by 10
Research works printed but not linked: 16
- Werner, 2008, Emergence and spread of vancomycin resistance among enterococci in Europe, Euro Surveill, 20, 13
- Patel, 2003, Clinical impact of vancomycin‐resistant enterococci, J Antimicrob Chemother, 51, iii13
- Kariyama, 1998, In‐vitro activity of the combination of ampicillin and arbekacin against high‐level gentamicin‐resistant enterococci, J Antimicrob Chemother, 42, 836, 10.1093/oxfordjournals.jac.a020872 · doi:10.1093/oxfordjournals.jac.a020872
- Saravolatz, 2009, Telavancin: a novel lipoglycopeptide, Clin Infect Dis, 49, 1908, 10.1086/648438 · doi:10.1086/648438
- Lefort, 2000, Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin‐susceptible or ‐resistantEnterococcus faecalis, Antimicrob Agents Chemother, 44, 3017, 10.1128/AAC.44.11.3017-3021.2000 · doi:10.1128/aac.44.11.3017-3021.2000
- Saleh‐Mghir, 1999, Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin‐resistantEnterococcus faecalis, Antimicrob Agents Chemother, 43, 115, 10.1128/AAC.43.1.115 · doi:10.1128/aac.43.1.115
- Tsai, 2006, Short course of linezolid treatment for vancomycin‐resistantEnterococcus faecium meningitis, Int J Clin Pract, 60, 740, 10.1111/j.1368-5031.2006.00706.x · doi:10.1111/j.1368-5031.2006.00706.x
- Bryson, 1996, Quinupristin‐dalfopristin, Drugs, 52, 406, 10.2165/00003495-199652030-00006 · doi:10.2165/00003495-199652030-00006
- Bethea, 2004, Treatment of vancomycin‐resistant enterococcus with quinupristin/dalfopristin and high‐dose ampicillin, Ann Pharmacother, 38, 989, 10.1345/aph.1D377 · doi:10.1345/aph.1d377
- Panesso, 2002, First characterization of a cluster of VanA‐type glycopeptide‐resistantEnterococcus faecium, Colombia, Emerg Infect Dis, 8, 961, 10.3201/eid0809.010435 · doi:10.3201/eid0809.010435
- Norris, 1995, Chloramphenicol for the treatment of vancomycin‐resistant enterococcal infections, Clin Infect Dis, 20, 1137, 10.1093/clinids/20.5.1137 · doi:10.1093/clinids/20.5.1137
- Ricaurte, 2001, Chloramphenicol treatment for vancomycin‐resistantEnterococcus faecium bacteremia, Clin Microbiol Infect, 7, 17, 10.1046/j.1469-0691.2001.00189.x · doi:10.1046/j.1469-0691.2001.00189.x
- Safdar, 2002, Prosthetic valve endocarditis due to vancomycin‐resistantEnterococcus faecium: treatment with chloramphenicol plus minocycline, Clin Infect Dis, 34, E61, 10.1086/340527 · doi:10.1086/340527
- Zinner, 2008, Selection of linezolid‐resistantEnterococcus faecium in an in vitro dynamic model: protective effect of doxycycline, J Antimicrob Chemother, 61, 629, 10.1093/jac/dkm542 · doi:10.1093/jac/dkm542
- Van Nieuwkoop, 2008, Chronic bacterial prostatitis and relapsingEnterococcus faecalis bacteraemia successfully treated with moxifloxacin, J Infect, 56, 155, 10.1016/j.jinf.2007.11.003 · doi:10.1016/j.jinf.2007.11.003
- Rambaldi, 1997, Combination of co‐trimoxazole and ciprofloxacin as therapy of a patient with infective endocarditis caused by an enterococcus highly resistant to gentamicin, J Antimicrob Chemother, 40, 737, 10.1093/jac/40.5.737 · doi:10.1093/jac/40.5.737
Cited by
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232
Intrinsic and acquired resistance mechanisms in enterococcus
Hollenbeck, B. L., & Rice, L. B. (2012) · Virulence · doi:10.4161/viru.21282 · Cited by 795
“faecalis.(23) Lincosamides and streptogramins.”
BackgroundCrank, C., & O'Driscoll, T. (2015) · Infection and Drug Resistance · doi:10.2147/idr.s54125 · Cited by 505
Hafez, H. M., & Attia, Y. A. (2020) · Frontiers in Veterinary Science · doi:10.3389/fvets.2020.00516 · Cited by 383
The rising problem of antimicrobial resistance in the intensive care unit
Brusselaers, N., Vogelaers, D., & Blot, S. (2011) · Annals of Intensive Care · doi:10.1186/2110-5820-1-47 · Cited by 350
Metadata
- Authors
- Arias, C. A., Contreras, G. A., & Murray, B. E.
- Venue
- Clinical Microbiology and Infection
- Publisher
- Elsevier BV
- Published
- 2010-06
- Volume
- 16
- Issue
- 6
- Pages
- 555-562
- ISSN
- 1198-743X (ISSN-L)
- OpenAlex
- W2103599303
- Cited by
- 388
- References
- 66
- FWCI
- 9.39
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 1642 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.